Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610132 | 1.00 | L3MBTL1 (0.43) | L3MBTL1CPA1ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL8887738 | 1.00 | L3MBTL1 (0.43) | L3MBTL1CPA1ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL2247539 | 1.00 | L3MBTL1 (0.43) | L3MBTL1CPA1ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL3872212 | 1.00 | L3MBTL1 (0.43) | L3MBTL1CPA1ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL18401160 | 0.86 | L3MBTL1 (0.34) | L3MBTL1ALDH1A1PTPN1 | |
| SCHEMBL8777473 | 0.82 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL2247734 | 0.81 | — | — | |
| SCHEMBL18686922 | 0.81 | L3MBTL1 (0.38) | L3MBTL1GLS | |
| SCHEMBL18686927 | 0.81 | L3MBTL1 (0.38) | L3MBTL1GLS | |
| SCHEMBL9280391 | 0.79 | L3MBTL1 (0.33) | L3MBTL1CPA1GLSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214928-A1 | Process for the preparation of marimastat, marimastat prepared by this process, a pharmaceutical composition comprising the same, and uses thereof | PIKRALIDA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-07-03 | — | — | US | claimed |
| EP-0754688-B1 | Dioxolane intermediates | BRITISH BIOTECH PHARM (GB) | 2000-12-27 | — | — | EP | claimed |
| US-5912360-A | Dioxolane intermediates | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-15 | — | — | US | claimed |
| EP-0754688-A2 | Dioxolane intermediates | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-01-22 | — | — | EP | claimed |
| JP-10204081-A | — | — | None | — | — | JP | disclosed |
| US-20250214928-A1 | Process for the preparation of marimastat, marimastat prepared by this process, a pharmaceutical composition comprising the same, and uses thereof | PIKRALIDA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-07-03 | — | — | US | disclosed |
| US-9550978-B2 | Isolation and functional identification of cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9550978-B2 | Isolation and functional identification of cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20130295636-A1 | Isolation and Functional Identification of Cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130295636-A1 | Isolation and Functional Identification of Cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| WO-2012062910-A1 | ISOLATION AND FUNCTIONAL IDENTIFICATION OF CELLS | CAPROTEC BIOANALYTICS GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-1996006074-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995019957-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| EP-0651739-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS. | BRITISH BIOTECH PHARM (GB) | 1995-05-10 | — | — | EP | disclosed |
| EP-0651738-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002446-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1994002447-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214928-A1 | Process for the preparation of marimastat, marimastat prepared by this process, a pharmaceutical composition comprising the same, and uses thereof | MMP7, MMP9, MMP3 | L3MBTL1 4648/4885CPA1 290/4885ALDH1A1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.